CN114667144A - Fak抑制剂在制备用于治疗nras突变的肿瘤的药物中的用途 - Google Patents

Fak抑制剂在制备用于治疗nras突变的肿瘤的药物中的用途 Download PDF

Info

Publication number
CN114667144A
CN114667144A CN202080078892.0A CN202080078892A CN114667144A CN 114667144 A CN114667144 A CN 114667144A CN 202080078892 A CN202080078892 A CN 202080078892A CN 114667144 A CN114667144 A CN 114667144A
Authority
CN
China
Prior art keywords
cancer
therapeutic agent
tumor
doxorubicin
fak inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080078892.0A
Other languages
English (en)
Inventor
王在琪
张江伟
江君
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yingshi Biotechnology Nanjing Co ltd
Original Assignee
Yingshi Biotechnology Nanjing Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yingshi Biotechnology Nanjing Co ltd filed Critical Yingshi Biotechnology Nanjing Co ltd
Publication of CN114667144A publication Critical patent/CN114667144A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

一种FAK抑制剂在制备用于预防和/或治疗NRAS突变的肿瘤的药物中的用途。一种治疗发生NRAS突变的肿瘤的方法，其包括向个体施用有效量的FAK抑制剂。用于治疗NRAS突变的肿瘤的FAK抑制剂。所述FAK抑制剂为BI853520、defactinib、GSK2256098、PF‑00562271、VS‑4718或其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (23)

  1. PCT国内申请，权利要求书已公开。
CN202080078892.0A 2019-11-18 2020-11-17 Fak抑制剂在制备用于治疗nras突变的肿瘤的药物中的用途 Pending CN114667144A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019111287949 2019-11-18
CN201911128794 2019-11-18
PCT/CN2020/129350 WO2021098679A1 (zh) 2019-11-18 2020-11-17 Fak抑制剂在制备用于治疗nras突变的肿瘤的药物中的用途

Publications (1)

Publication Number Publication Date
CN114667144A true CN114667144A (zh) 2022-06-24

Family

ID=75981319

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080078892.0A Pending CN114667144A (zh) 2019-11-18 2020-11-17 Fak抑制剂在制备用于治疗nras突变的肿瘤的药物中的用途

Country Status (11)

Country Link
US (2) US20230145356A1 (zh)
EP (1) EP4062914A4 (zh)
JP (1) JP2023503897A (zh)
KR (1) KR20220101677A (zh)
CN (1) CN114667144A (zh)
AU (1) AU2020388848A1 (zh)
BR (1) BR112022009571A2 (zh)
CA (1) CA3158585A1 (zh)
MX (1) MX2022005994A (zh)
PE (1) PE20221259A1 (zh)
WO (1) WO2021098679A1 (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023104151A1 (zh) * 2021-12-10 2023-06-15 应世生物科技(南京)有限公司 治疗肿瘤的药物组合及用途
WO2024037498A1 (zh) * 2022-08-15 2024-02-22 海创药业股份有限公司 一种治疗卵巢癌的联合用药物
WO2024041527A1 (zh) * 2022-08-24 2024-02-29 应世生物科技(南京)有限公司 Fak抑制剂及微管抑制剂的药物组合及用途
WO2024067631A1 (zh) * 2022-09-30 2024-04-04 应世生物科技(南京)有限公司 Fak抑制剂及诱导免疫原性细胞死亡的物质的药物组合及用途

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021104454A1 (zh) * 2019-11-28 2021-06-03 应世生物科技(南京)有限公司 Bi853520在癌症治疗中的用途
CN115052603B (zh) * 2020-02-05 2023-12-19 应世生物科技(南京)有限公司 Bi853520与化疗药物的联用
CN116096713A (zh) * 2020-08-03 2023-05-09 应世生物科技(南京)有限公司 化合物的固体形式
CN113855695B (zh) * 2021-11-01 2023-06-06 上海理工大学 一种结肠释药口服复方药物组合物及其制备方法
CN114681471B (zh) * 2022-01-19 2023-06-06 杭州师范大学 一种硼替佐米和榄香烯分子配伍药物组合及其应用
WO2023138630A1 (zh) * 2022-01-21 2023-07-27 应世生物科技(南京)有限公司 治疗肿瘤的药物组合及用途
CN116889565A (zh) * 2022-04-07 2023-10-17 深圳微芯生物科技股份有限公司 西奥罗尼在抗胰腺癌中的用途
WO2023246869A1 (zh) 2022-06-24 2023-12-28 应世生物科技(南京)有限公司 治疗肿瘤的药物组合及用途
WO2024051679A1 (zh) * 2022-09-05 2024-03-14 应世生物科技(南京)有限公司 Fak抑制剂及egfr-tki的药物组合及用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102292322A (zh) * 2008-11-24 2011-12-21 贝林格尔.英格海姆国际有限公司 用于治疗例如癌症的疾病的取代的嘧啶
US20160346282A1 (en) * 2014-02-07 2016-12-01 Verastem, Inc. Methods and compositions for treating abnormal cell growth
CN108289892A (zh) * 2015-06-29 2018-07-17 维瑞斯特姆股份有限公司 治疗组合物、组合和使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022547358A (ja) * 2019-09-13 2022-11-14 ジ インスティテュート オブ キャンサー リサーチ：ロイヤル キャンサー ホスピタル 治療組成物、組み合わせ、及び使用方法
CN115052603B (zh) * 2020-02-05 2023-12-19 应世生物科技(南京)有限公司 Bi853520与化疗药物的联用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102292322A (zh) * 2008-11-24 2011-12-21 贝林格尔.英格海姆国际有限公司 用于治疗例如癌症的疾病的取代的嘧啶
US20160346282A1 (en) * 2014-02-07 2016-12-01 Verastem, Inc. Methods and compositions for treating abnormal cell growth
CN108289892A (zh) * 2015-06-29 2018-07-17 维瑞斯特姆股份有限公司 治疗组合物、组合和使用方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HIRT等: "Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor pgenotype", ONCOGENESIS, vol. 7, no. 2, pages 1, XP055813570, DOI: 10.1038/s41389-018-0032-z *
LEE等: "FAK signaling in human cancer as a target for therapeutics", PHARMACOLOGY & THERAPEUTICS, vol. 146, pages 141 - 144 *
TIEDE等: "The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer", ONCOGENESIS, vol. 7, no. 9, pages 1, XP055813573, DOI: 10.1038/s41389-018-0083-1 *
ZHANG等: "Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways", BRITISH JOURNAL OF CANCER, vol. 115, no. 2, pages 1 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023104151A1 (zh) * 2021-12-10 2023-06-15 应世生物科技(南京)有限公司 治疗肿瘤的药物组合及用途
WO2024037498A1 (zh) * 2022-08-15 2024-02-22 海创药业股份有限公司 一种治疗卵巢癌的联合用药物
WO2024041527A1 (zh) * 2022-08-24 2024-02-29 应世生物科技(南京)有限公司 Fak抑制剂及微管抑制剂的药物组合及用途
WO2024067631A1 (zh) * 2022-09-30 2024-04-04 应世生物科技(南京)有限公司 Fak抑制剂及诱导免疫原性细胞死亡的物质的药物组合及用途

Also Published As

Publication number Publication date
US20230145356A1 (en) 2023-05-11
EP4062914A4 (en) 2024-01-17
KR20220101677A (ko) 2022-07-19
WO2021098679A1 (zh) 2021-05-27
BR112022009571A2 (pt) 2022-08-02
CA3158585A1 (en) 2021-05-27
US20230364088A1 (en) 2023-11-16
EP4062914A1 (en) 2022-09-28
MX2022005994A (es) 2022-06-17
JP2023503897A (ja) 2023-02-01
AU2020388848A1 (en) 2022-05-26
PE20221259A1 (es) 2022-08-16

Similar Documents

Publication Publication Date Title
CN114667144A (zh) Fak抑制剂在制备用于治疗nras突变的肿瘤的药物中的用途
CN106659716B (zh) 阿吡莫德组合物及其使用方法
AU2011290818B2 (en) Combination anti - cancer therapy
US20120128670A1 (en) mTOR INHIBITOR AND ANGIOGENESIS INHIBITOR COMBINATION THERAPY
WO2022111714A1 (zh) 用于治疗pik3ca突变癌症的组合疗法
WO2019109074A1 (en) Mebendazole cancer therapies and methods of use
CA3222772A1 (en) Erk1/2 and shp2 inhibitors combination therapy
KR20070029185A (ko) 옥살리플라틴 및 ｅｇｆｒ­억제제로의 치료
WO2023138630A1 (zh) 治疗肿瘤的药物组合及用途
WO2023099763A1 (en) Sirt6 inhibitors for use in treating resistant hrd cancer
EP2981279B1 (en) Marcks inhibitor peptides for inhibiting metastasis
JP2009509974A (ja) 抗癌治療
CN113597309A (zh) 抗肿瘤组合物
WO2024088193A1 (en) Combination of aurora a and parp inhibitors for treatment of cancers
US20240108721A1 (en) Dual targeting chimeric antigen receptors
CN117897158A (zh) Erk1/2和shp2抑制剂组合疗法
CA3231639A1 (en) Triple-agent therapy for cancer treatment
Weller et al. New Approaches to Brain Tumor Therapy
KR20240044419A (ko) Erk1/2 및 egfr 억제제 조합 요법
WO2023196910A1 (en) Methods of treating solid tumor using (19r)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-amine
WO2022271939A1 (en) Erk1/2 and cdk4/6 inhibitors combination therapy
CN117858725A (zh) Erk1/2和egfr抑制剂组合疗法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40078044

Country of ref document: HK